# A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

> **NCT05254743** · PHASE3 · RECRUITING · sponsor: **Loxo Oncology, Inc.** · enrollment: 662 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Leukemia, Lymphocytic
- Leukemia, B-cell
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Pirtobrutinib
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT05254743
- **Lead sponsor:** Loxo Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-22
- **Primary completion:** 2025-06-10
- **Final completion:** 2028-01
- **Target enrollment:** 662 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05254743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05254743, "A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05254743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*